Cell-based screening approach for antitumor drug leads which exploits sensitivity differences between normal and...

Area of Science:

• Oncology
• Drug Discovery
• Cell Biology

Background:

• Developing effective antitumor drugs requires identifying compounds with selective toxicity towards cancer cells.
• High-throughput screening (HTS) methods are crucial for efficiently evaluating large compound libraries for potential drug leads.

Purpose of the Study:

• To develop and validate a cell-based, in vitro screening approach for identifying novel antitumor drug candidates.
• To exploit differential drug sensitivity between normal and cancer cells for selective drug lead identification.

Main Methods:

• A three-step, high-throughput screening (HTS) assay was designed.
• Antiproliferative and cytotoxic activities were measured over 7 days using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay.
• The assay utilized panels of proliferating primary human cells and established cancer cell lines.

Main Results:

• Proof-of-concept experiments correctly identified 11 known anticancer drugs from a mixture of 5000 compounds.
• Screening a library of 110,000 compounds identified novel chemical classes with in vitro activity against an expanded panel of cancer cell lines.
• Two novel compounds identified as mitotic inhibitors demonstrated in vivo potency against breast cancer xenografts (MDA-MB-435).

Conclusions:

• The developed cell-based screening approach is effective for identifying potential antitumor drug leads.
• The identified novel mitotic inhibitors show promise for further development as breast cancer therapeutics.